Shenzhen Chipscreen Biosciences' high P/E ratio, resulting from a strong share price surge, may be concerning due to the anticipated EPS slump. The company's shrinking earnings outlook isn't impacting its high P/E as much as expected, potentially leading to future shareholder disappointment.
The company's debt usage and EBIT loss over the past year, slow revenue growth, weak balance sheet, and cash burn rate all contribute to the stock's perceived riskiness, despite potential for future improvement.
Despite the high P/S ratio, shareholders seem confident in Shenzhen Chipscreen Biosciences' future revenues, which is supporting the share price. The high P/S ratio is justified by the company's strong future revenue growth.
Shenzhen Chipscreen Biosciencesに関するコメント
まだコメントはありません